Sanofi Pasteur In Deal With Crucell For Rabies Antibody Cocktail
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II mAb cocktail is potential next-generation replacement for serum-derived immunoglobulin with rabies vaccine in post-bite therapy.
You may also be interested in...
Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
Crucell would fit Wyeth’s ongoing effort to extend geographic base for vaccines and provide new candidates and technologies to provide depth to the company’s vaccine R&D effort.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.